707 related articles for article (PubMed ID: 15569371)
21. Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry.
Ramel S; Reid BJ; Sanchez CA; Blount PL; Levine DS; Neshat K; Haggitt RC; Dean PJ; Thor K; Rabinovitch PS
Gastroenterology; 1992 Apr; 102(4 Pt 1):1220-8. PubMed ID: 1551529
[TBL] [Abstract][Full Text] [Related]
22. Detection of the risk of adenocarcinoma in Barrett's esophagus by means of tumor markers (p53 and Ki67).
Trakál E; Guidi A; Butti AL; Trakál JJ; Sambuelli R; Zárate FE
Acta Gastroenterol Latinoam; 2010 Sep; 40(3):211-5. PubMed ID: 21049770
[TBL] [Abstract][Full Text] [Related]
23. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins.
Chatelain D; Fléjou JF
Virchows Arch; 2003 Jan; 442(1):18-24. PubMed ID: 12536310
[TBL] [Abstract][Full Text] [Related]
24. Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett's-associated neoplasia: correlation with prognosis.
Yacoub L; Goldman H; Odze RD
Mod Pathol; 1997 Feb; 10(2):105-12. PubMed ID: 9127315
[TBL] [Abstract][Full Text] [Related]
25. [Histochemical diagnosis of short segment Barrett's esophagus].
Fujiyama Y; Ishizuka I; Koyama S
Nihon Rinsho; 2005 Aug; 63(8):1420-6. PubMed ID: 16101233
[TBL] [Abstract][Full Text] [Related]
26. Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma.
Lord RV; Brabender J; Wickramasinghe K; DeMeester SR; Holscher A; Schneider PM; Danenberg PV; DeMeester TR
Surgery; 2005 Nov; 138(5):924-31. PubMed ID: 16291394
[TBL] [Abstract][Full Text] [Related]
27. Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma.
Bani-Hani K; Martin IG; Hardie LJ; Mapstone N; Briggs JA; Forman D; Wild CP
J Natl Cancer Inst; 2000 Aug; 92(16):1316-21. PubMed ID: 10944553
[TBL] [Abstract][Full Text] [Related]
28. The value of p53 and Ki67 as markers for tumour progression in the Barrett's dysplasia-carcinoma sequence.
Polkowski W; van Lanschot JJ; Ten Kate FJ; Baak JP; Tytgat GN; Obertop H; Voorn WJ; Offerhaus GJ
Surg Oncol; 1995 Jun; 4(3):163-71. PubMed ID: 7582189
[TBL] [Abstract][Full Text] [Related]
29. MCM4 and MCM7, potential novel proliferation markers, significantly correlated with Ki-67, Bmi1, and cyclin E expression in esophageal adenocarcinoma, squamous cell carcinoma, and precancerous lesions.
Choy B; LaLonde A; Que J; Wu T; Zhou Z
Hum Pathol; 2016 Nov; 57():126-135. PubMed ID: 27476776
[TBL] [Abstract][Full Text] [Related]
30. Expression of the p53 homologue p63alpha and DeltaNp63alpha in the neoplastic sequence of Barrett's oesophagus: correlation with morphology and p53 protein.
Hall PA; Woodman AC; Campbell SJ; Shepherd NA
Gut; 2001 Nov; 49(5):618-23. PubMed ID: 11600462
[TBL] [Abstract][Full Text] [Related]
31. Paget cells in the esophagus: assessment of their histopathologic features and near-universal association with underlying esophageal adenocarcinoma.
Abraham SC; Wang H; Wang KK; Wu TT
Am J Surg Pathol; 2008 Jul; 32(7):1068-74. PubMed ID: 18496141
[TBL] [Abstract][Full Text] [Related]
32. Analysis of Ki-67, p53 and Bcl-2 expression in the dysplasia-carcinoma sequence of Barrett's esophagus.
Rioux-Leclercq N; Turlin B; Sutherland F; Heresbach N; Launois B; Campion JP; Ramee MP
Oncol Rep; 1999; 6(4):877-82. PubMed ID: 10373674
[TBL] [Abstract][Full Text] [Related]
33. Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation.
Kimchi ET; Posner MC; Park JO; Darga TE; Kocherginsky M; Karrison T; Hart J; Smith KD; Mezhir JJ; Weichselbaum RR; Khodarev NN
Cancer Res; 2005 Apr; 65(8):3146-54. PubMed ID: 15833844
[TBL] [Abstract][Full Text] [Related]
34. Predictive value of p53, Ki67 and TLR5 in neoplastic progression of Barrett's esophagus: a matched case-control study.
Helminen O; Melkko J; Saarnio J; Sihvo E; Kuopio T; Ohtonen P; Kauppila JH; Karttunen TJ; Huhta H
Virchows Arch; 2022 Sep; 481(3):467-476. PubMed ID: 35614270
[TBL] [Abstract][Full Text] [Related]
35. Mucin expression and proliferating cell index of esophageal Barrett's adenocarcinoma.
Yamamoto S; Kijima H; Hara T; Chino O; Shimada H; Tanaka M; Inokuchi S; Makuuchi H
Int J Mol Med; 2005 Sep; 16(3):375-80. PubMed ID: 16077942
[TBL] [Abstract][Full Text] [Related]
36. Histopathologic evaluation of an animal model for Barrett's esophagus and adenocarcinoma of the distal esophagus.
Buskens CJ; Hulscher JB; van Gulik TM; Ten Kate FJ; van Lanschot JJ
J Surg Res; 2006 Oct; 135(2):337-44. PubMed ID: 16926029
[TBL] [Abstract][Full Text] [Related]
37. Barrett's esophagus: metaplastic cells with loss of heterozygosity at the APC gene locus are clonal precursors to invasive adenocarcinoma.
Zhuang Z; Vortmeyer AO; Mark EJ; Odze R; Emmert-Buck MR; Merino MJ; Moon H; Liotta LA; Duray PH
Cancer Res; 1996 May; 56(9):1961-4. PubMed ID: 8616831
[TBL] [Abstract][Full Text] [Related]
38. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus.
Schneider PM; Stoeltzing O; Roth JA; Hoelscher AH; Wegerer S; Mizumoto S; Becker K; Dittler HJ; Fink U; Siewert JR
Clin Cancer Res; 2000 Aug; 6(8):3153-8. PubMed ID: 10955797
[TBL] [Abstract][Full Text] [Related]
39. Cdx2 expression and its promoter methylation during metaplasia-dysplasia-carcinoma sequence in Barrett's esophagus.
Makita K; Kitazawa R; Semba S; Fujiishi K; Nakagawa M; Haraguchi R; Kitazawa S
World J Gastroenterol; 2013 Jan; 19(4):536-41. PubMed ID: 23382633
[TBL] [Abstract][Full Text] [Related]
40. Malignant progression in Barrett's esophagus: pathology and molecular biology.
Mueller J; Werner M; Siewert JR
Recent Results Cancer Res; 2000; 155():29-41. PubMed ID: 10693236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]